SCHEMBL1011423

SCHEMBL1011423

COc1cnc(NC(=O)Oc2ccccc2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
GAA P10253 3/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CCNE1 P24864 1/20 0.47
CDK2 P24941 1/20 0.47
CDK5 Q00535 1/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 2/20 0.45
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
KDM4E B2RXH2 2/20 0.43
THRB P10828 1/20 0.43
GFER P55789 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31028805 1.00 ALDH1A1 (0.50) ALDH1A1GAAHTTSMN1; SMN2CCNE1
SCHEMBL27785476 0.86 ALDH1A1 (0.41) ALDH1A1GAAHTTSMN1; SMN2CCNE1
SCHEMBL16776510 0.86 FAAH (0.45) ALDH1A1GAAHTTSMN1; SMN2CCNE1
SCHEMBL32672176 0.86 FAAH (0.45) ALDH1A1GAAHTTSMN1; SMN2CCNE1
SCHEMBL32672056 0.82 NOTUM (0.52) ALDH1A1GAAHTTSMN1; SMN2CCNE1
SCHEMBL305046 0.82 NOTUM (0.52) ALDH1A1GAAHTTSMN1; SMN2CCNE1
SCHEMBL32672041 0.81 GPR119 (0.47) ALDH1A1GAAHTTSMN1; SMN2CCNE1
SCHEMBL2595570 0.81 CCNE1 (0.47) ALDH1A1GAAHTTSMN1; SMN2CCNE1
SCHEMBL590618 0.80 KMT2A (0.61) ALDH1A1GAAHTTSMN1; SMN2MAPT
SCHEMBL2644869 0.80 CCNE1 (0.47) ALDH1A1GAAHTTSMN1; SMN2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC ALDH1A1 360/4885GAA 402/4885HTT 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.